IGC Pharma Inc
IGS1
Company Profile
Business description
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer’s disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer’s disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer’s cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer’s disease, such as plaques or tangles.
Contact
10224 Falls Road
PotomacMD20854
USAT: +1 301 983-0998
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 March 2026
Employees
70
Stocks News & Analysis
stocks
BlackRock earnings: Market gains and inflows drive AUM and revenue to record highs
We plan to raise our fair value estimate of BlackRock stock.
stocks
Our view of ANZ’s strategic plan
Trying to please customers and shareholders with a simpler and leaner bank.
stocks
Perplexing buyback from overvalued ASX share
Earnings continue to grow but investor expectations are too high.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,299.00 | 21.90 | 0.24% |
| CAC 40 | 8,077.00 | 157.38 | 1.99% |
| DAX 40 | 24,210.98 | 25.96 | -0.11% |
| Dow JONES (US) | 46,371.91 | 101.45 | 0.22% |
| FTSE 100 | 9,424.75 | 28.02 | -0.30% |
| HKSE | 25,910.60 | 469.25 | 1.84% |
| NASDAQ | 22,671.41 | 149.71 | 0.66% |
| Nikkei 225 | 47,672.67 | 825.35 | 1.76% |
| NZX 50 Index | 13,307.40 | 30.41 | 0.23% |
| S&P 500 | 6,674.45 | 30.14 | 0.45% |
| S&P/ASX 200 | 8,990.90 | 22.20 | 0.25% |
| SSE Composite Index | 3,912.21 | 46.98 | 1.22% |